Climb Bio Inc
CLYMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeClimb Bio Inc operates in the Biotechnology space. Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. At a $627.6M market cap, Climb Bio Inc ranks as a small-cap company within healthcare. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Market Cap
$627.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-9.77
EPS (TTM)
$-0.77
EPS (Fwd)
$-1.12
ROE
-30.9%
ROA
-21.3%
Cash
$109.6M
Total Debt
$479,000
Free CF
-$34.2M
52W Change
828.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $109.6M in cash comfortably exceeding the $479K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$34.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -30.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CLYM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Climb Bio Inc's trajectory.